PHARMACEUTICAL PREPARATIONS REAGENTS

Brand Owner (click to sort) Address Description
COGNOSTICS Memory Pharmaceuticals Corporation 100 Philips Parkway Montvale NJ 07645 pharmaceutical preparations and reagents for clinical medical use, namely, pharmaceutical preparations and reagents for use in high throughput screening, in vivo pharmacology, and physiological assays which are related to the discovery, characterization, and selection of pharmaceuticals for affecting the central nervous system of humans and animals;Reagents intended for scientific or medical research use in the field of pharmaceuticals affecting the central nervous system of humans and animals;
MEMORY Memory Pharmaceuticals Corp. 100 Philips Parkway Montevale NJ 07645 PHARMACEUTICAL PREPARATIONS AND REAGENTS FOR CLINICAL OR MEDICAL USE, NAMELY, PHARMACEUTICAL PREPARATIONS AND REAGENTS FOR USE IN HIGH THROUGHPUT SCREENING, IN VIVO PHARMACOLOGY, PHYSIOLOGICAL ASSAYS, AND THE LIKE RELATED TO THE DISCOVERY, CHARACTERIZATION, AND SELECTION OF PHARMACEUTICALS FOR AFFECTING THE CENTRAL NERVOUS SYSTEM OF HUMANS AND ANIMALS;PHARMACEUTICAL PREPARATIONS AND REAGENTS FOR SCIENTIFIC OR RESEARCH USE, NAMELY, PHARMACEUTICAL PREPARATIONS AND REAGENTS FOR USE IN HIGH THROUGHPUT SCREENING, IN VIVO PHARMACOLOGY, PHYSIOLOGICAL ASSAYS, AND THE LIKE RELATED TO THE DISCOVERY, CHARACTERIZATION, AND SELECTION OF PHARMACEUTICALS FOR AFFECTING THE CENTRAL NERVOUS SYSTEM OF HUMANS AND ANIMALS;MEMORY;MEDICAL AND SCIENTIFIC RESEARCH, PRODUCT RESEARCH AND DEVELOPMENT, AND TESTING, ANALYSIS AND EVALUATION OF THE GOODS AND SERVICES OF OTHERS FOR PHARMACEUTICALS AFFECTING THE CENTRAL NERVOUS SYSTEM OF HUMANS AND ANIMALS;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for treating secretory diarrhea. The compositions and pharmaceutical preparations of the invention may comprise one or more thiazolidinone compounds, and may additionally comprise one or more pharmaceutically acceptable carriers, excipients, and/or diluents.